Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-21), Dishman Carbogen Amics's 3-1 Month Momentum % is -10.24%.
The industry rank for Dishman Carbogen Amics's 3-1 Month Momentum % or its related term are showing as below:
NSE:DCAL's 3-1 Month Momentum % is ranked worse than 55.56% of 1386
companies
in the Biotechnology industry
Industry Median: -7.01
vs NSE:DCAL: -10.24
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Dishman Carbogen Amics 3-1 Month Momentum % Related Terms
NSE:DCAL vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Dishman Carbogen Amics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dishman Carbogen Amics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Dishman Carbogen Amics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dishman Carbogen Amics (NSE:DCAL) has a 3-1 Month Momentum % of -10.24% as of Aug. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dishman Carbogen Amics and its competitors. According to the industry distribution chart, Dishman Carbogen Amics ranks #770 out of 1386 companies in the Biotechnology industry, placing it in the top 55.6%.
Is Dishman Carbogen Amics' 3-1 Month Momentum % too high?
Dishman Carbogen Amics' current 3-1 Month Momentum % is -10.24%. Based on the distribution chart, Dishman Carbogen Amics ranks #770 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dishman Carbogen Amics has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dishman Carbogen Amics ranks #770 out of 1386 companies for 3-1 Month Momentum %. This places Dishman Carbogen Amics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dishman Carbogen Amics and its competitors. Dishman Carbogen Amics's current 3-1 Month Momentum % is -10.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (NSE:DCAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹239.66, compared to a current price of ₹173.54 — trading 27.6% below its estimated fair value. The current 3-1 Month Momentum % is -10.24%. Dishman Carbogen Amics' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Dishman Carbogen Amics (NSE:DCAL), the current 3-1 Month Momentum % is -10.24% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?
Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued.
The current stock price of ₹173.54 is trading 27.6% below its estimated GF Value™ of ₹239.66.
GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.
Key valuation signals for NSE:DCAL:
3-1 Month Momentum %: -10.24%
GF Value™: ₹239.66 vs. price of ₹173.54 (27.6% below fair value)
No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
72GF Score
Get the complete analysis for NSE:DCAL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DCAL has been successfully added to your 
